Publication
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
Authors not recorded
Cancer Res2010PMID 20179196PMC2832818stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugAfimoxifenecivic_curation1.00
- geneFGFR1civic_curation1.00
- variantFGFR1 Amplificationcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 20179196
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR1 Amplification1 | ||||||||
| Afimoxifene | Malignant Breast Neoplasm | Predictive | D | Supports Resistance | 3 | accepted | EID1105FGFR1-amplified breast cancer cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1. PMID 20179196 · Turner et al., 2010 · Open in CIViC | civic |